Literature DB >> 25960933

Stress-related and homeostatic cytokines regulate Vγ9Vδ2 T-cell surveillance of mevalonate metabolism.

Georg Gruenbacher1, Oliver Nussbaumer2, Hubert Gander1, Bernhard Steiner1, Nicolai Leonhartsberger1, Martin Thurnher1.   

Abstract

The potentially oncogenic mevalonate pathway provides building blocks for protein prenylation and induces cell proliferation and as such is an important therapeutic target. Among mevalonate metabolites, only isopentenyl pyrophosphate (IPP) has been considered to be an immunologically relevant antigen for primate-specific, innate-like Vγ9Vδ2 T cells with antitumor potential. We show here that Vγ9Vδ2 T cells pretreated with the stress-related, inflammasome-dependent cytokine interleukin 18 (IL-18) were potently activated not only by IPP but also by all downstream isoprenoid pyrophosphates that exhibit combined features of antigens and cell-extrinsic metabolic cues. Vγ9Vδ2 T cells induced this way effectively proliferated even under severe lymphopenic conditions and the antioxidant N-acetylcysteine significantly improved reconstitution of γδ T cells predominantly with a central memory phenotype. The homeostatic cytokine IL-15 induced the differentiation of effector cells in an antigen-independent fashion, which rapidly produced abundant interferon γ (IFNγ) upon antigen re-encounter. IL-15 induced effector γδ T cells displayed increased levels of the cytotoxic lymphocyte-associated proteins CD56, CD96, CD161 and perforin. In response to stimulation with isoprenoid pyrophosphates, these effector cells upregulated surface expression of CD107a and exhibited strong cytotoxicity against tumor cells in vitro. Our data clarify understanding of innate immunosurveillance mechanisms and will facilitate the controlled generation of robust Vγ9Vδ2 T cell subsets for effective cancer immunotherapy.

Entities:  

Keywords:  BTN, butyrophilin; CD107a; CD56; CFSE, carboxyfluorescein succinimidyl ester; DMAPP, dimethylallyl pyrophosphate; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; GPP, geranyl pyrophosphate; IL-15; IL-18; IPP, isopentenyl pyrophosphate; N-BP, nitrogen-containing bisphosphonate; NAC, N-acetylcysteine; NK, natural killer; TCR, T cell receptor; immune surveillance; metabolic cues; mevalonate pathway; γδ T cells

Year:  2014        PMID: 25960933      PMCID: PMC4368140          DOI: 10.4161/21624011.2014.953410

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  68 in total

1.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 2.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.

Authors:  Panagiotis A Konstantinopoulos; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Nat Rev Drug Discov       Date:  2007-07       Impact factor: 84.694

Review 3.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

4.  CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.

Authors:  L J Zhou; T F Tedder
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 5.  Inflammasomes in carcinogenesis and anticancer immune responses.

Authors:  Laurence Zitvogel; Oliver Kepp; Lorenzo Galluzzi; Guido Kroemer
Journal:  Nat Immunol       Date:  2012-03-18       Impact factor: 25.606

6.  Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset.

Authors:  Christelle Harly; Yves Guillaume; Steven Nedellec; Cassie-Marie Peigné; Hannu Mönkkönen; Jukka Mönkkönen; Jianqiang Li; Jürgen Kuball; Erin J Adams; Sonia Netzer; Julie Déchanet-Merville; Alexandra Léger; Thomas Herrmann; Richard Breathnach; Daniel Olive; Marc Bonneville; Emmanuel Scotet
Journal:  Blood       Date:  2012-07-05       Impact factor: 22.113

Review 7.  Novel aspects of mevalonate pathway inhibitors as antitumor agents.

Authors:  Martin Thurnher; Oliver Nussbaumer; Georg Gruenbacher
Journal:  Clin Cancer Res       Date:  2012-04-23       Impact factor: 12.531

8.  Dysregulation of the mevalonate pathway promotes transformation.

Authors:  James W Clendening; Aleks Pandyra; Paul C Boutros; Samah El Ghamrasni; Fereshteh Khosravi; Grace A Trentin; Anna Martirosyan; Anne Hakem; Razqallah Hakem; Igor Jurisica; Linda Z Penn
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-09       Impact factor: 11.205

9.  Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox.

Authors:  Ling Yao; Yan Zhang; Keying Chen; Xiaofang Hu; Lisa X Xu
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

10.  Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites.

Authors:  Francesco Dieli; Fabrizio Poccia; Martin Lipp; Guido Sireci; Nadia Caccamo; Caterina Di Sano; Alfredo Salerno
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

View more
  25 in total

Review 1.  Trial Watch-Immunostimulation with cytokines in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

2.  Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.

Authors:  Morgane Moulin; Javier Alguacil; Siyi Gu; Asmaa Mehtougui; Erin J Adams; Suzanne Peyrottes; Eric Champagne
Journal:  Cell Mol Life Sci       Date:  2017-07-01       Impact factor: 9.261

Review 3.  Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.

Authors:  José Saura-Esteller; Milon de Jong; Lisa A King; Erik Ensing; Benjamin Winograd; Tanja D de Gruijl; Paul W H I Parren; Hans J van der Vliet
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

4.  Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.

Authors:  Jiannong Li; Inna Smalley; Zhihua Chen; Jheng-Yu Wu; Manali S Phadke; Jamie K Teer; Thanh Nguyen; Florian A Karreth; John M Koomen; Amod A Sarnaik; Jonathan S Zager; Nikhil I Khushalani; Ahmad A Tarhini; Vernon K Sondak; Paulo C Rodriguez; Jane L Messina; Y Ann Chen; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

5.  Low dose gemcitabine increases the cytotoxicity of human Vγ9Vδ2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model.

Authors:  Teruki Shimizu; Mako Tomogane; Masatsugu Miyashita; Osamu Ukimura; Eishi Ashihara
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

6.  Dichotomous and stable gamma delta T-cell number and function in healthy individuals.

Authors:  Lingling Ou; Huaishan Wang; Qin Liu; Jie Zhang; Hezhe Lu; Liangping Luo; Changzheng Shi; Shaoqiang Lin; Liyun Dong; Yeye Guo; Lili Huang; Jinjin Zhu; Xiangfan Yin; Alexander C Huang; Giorgos Karakousis; Lynn Schuchter; Ravi Amaravadi; Cathy Zheng; Yi Fan; Wei Guo; Xiaowei Xu
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

Review 7.  CD56 in the Immune System: More Than a Marker for Cytotoxicity?

Authors:  Heleen H Van Acker; Anna Capsomidis; Evelien L Smits; Viggo F Van Tendeloo
Journal:  Front Immunol       Date:  2017-07-24       Impact factor: 7.561

8.  The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells.

Authors:  Barbara Castella; Joanna Kopecka; Patrizia Sciancalepore; Giorgia Mandili; Myriam Foglietta; Nico Mitro; Donatella Caruso; Francesco Novelli; Chiara Riganti; Massimo Massaia
Journal:  Nat Commun       Date:  2017-06-05       Impact factor: 14.919

9.  Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.

Authors:  Heleen H Van Acker; Ottavio Beretta; Sébastien Anguille; Lien De Caluwé; Angela Papagna; Johan M Van den Bergh; Yannick Willemen; Herman Goossens; Zwi N Berneman; Viggo F Van Tendeloo; Evelien L Smits; Maria Foti; Eva Lion
Journal:  Oncotarget       Date:  2017-02-21

10.  Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells.

Authors:  Heleen H Van Acker; Sébastien Anguille; Yannick Willemen; Johan M Van den Bergh; Zwi N Berneman; Eva Lion; Evelien L Smits; Viggo F Van Tendeloo
Journal:  J Hematol Oncol       Date:  2016-09-29       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.